{
    "Trade/Device Name(s)": [
        "Elecsys\u00ae proBNP II Immunoassay",
        "Elecsys\u00ae PreciControl Cardiac II",
        "Elecsys\u00ae proBNP II CalSet"
    ],
    "Submitter Information": "Roche Diagnostics Corporation",
    "510(k) Number": "K072437",
    "Predicate Device Reference 510(k) Number(s)": [
        "K051382",
        "K032089",
        "K022516"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBC",
        "JJY",
        "JIT"
    ],
    "Summary Letter Date": "January 29, 2008",
    "Summary Letter Received Date": "January 30, 2008",
    "Submission Date": "January 28, 2008",
    "Regulation Number(s)": [
        "21CFR862.1117"
    ],
    "Regulation Name(s)": [
        "B-Type Natriuretic Peptide"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "cardiac"
    ],
    "Analyte(s)": [
        "N-terminal pro-Brain natriuretic peptide (NT-proBNP)",
        "CK-MB",
        "Digoxin",
        "Myoglobin",
        "Digitoxin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Elecsys 1010",
        "Elecsys 2010",
        "cobas e 411",
        "MODULAR ANALYTICS E170 (Elecsys module)",
        "cobas e 601"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemiluminescence immunoassay (ECLIA)",
        "Sandwich immunoassay"
    ],
    "Methodologies": [
        "Immunoassay",
        "Electrochemiluminescence detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Elecsys proBNP II Immunoassay, PreciControl Cardiac II, and proBNP II CalSet for quantitative NT-proBNP determination in human serum/plasma for cardiac assessment using ECLIA on Elecsys/cobas analyzers",
    "Indications for Use Summary": "Immunoassay for quantitative determination of NT-proBNP in serum and plasma as an aid in diagnosing congestive heart failure, risk stratification of acute coronary syndrome and heart failure, and assessment of cardiovascular risk in stable coronary artery disease patients",
    "fda_folder": "Clinical Chemistry"
}